Literature DB >> 12750288

p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.

Monika Phelps1, Matthew Darley, John N Primrose, Jeremy P Blaydes.   

Abstract

The negative-regulatory feedback loop between p53 and hdm2 forms part of a finely balanced regulatory network of proteins that controls cell cycle progression and commitment to apoptosis. Expression of hdm2, and its mouse orthologue mdm2, is known to be induced by p53, but recent evidence has demonstrated mdm2 expression can also be regulated via p53-independent pathways. However the p53 independent mechanisms that control transcription of the human hdm2 gene have not been studied. Differential levels of hdm2 mRNA and protein expression have been reported in several types of human malignancy, including breast cancers in which hdm2 expression correlates with positive estrogen receptor alpha (ERalpha) status. Experimental models have demonstrated that hdm2 overexpression can promote breast cancer development. Here, we show that the elevated level of hdm2 protein in ERalpha(+ve) breast cancer cell lines such as MCF-7 and T47D is because of transcription from the p53-inducible P2 promoter of hdm2. The P2 promoter is inactive in ERalpha(-ve) cell lines such as SKBr3. Hdm2-P2 promoter activity in T47D cells is independent of p53, as well as of known regulators of the mouse mdm2-P2 promoter, including ERalpha and ras-raf-mitogen-activated protein/extracellular signal-regulated kinase (MEK) mitogen-activated protein kinase (MAPK) signaling. We show that hdm2-P2 activity in T47D cells is dependent on the integrity of both an evolutionarily conserved composite binding site for AP1 and ETS family transcription factors (AP1-ETS) and a nonconserved upstream (nnGGGGC)(5) repeat sequence. Lack of hdm2-P2 activity in ERalpha(-ve) cells is shown to be a consequence of reduced transcriptional activation through the AP1-ETS element. Overexpression of ETS2 in SKBr3 cells reconstitutes AP1-ETS element-dependent hdm2-P2 promoter activity, resulting in increased levels of hdm2 protein in the cells. Our findings support the hypothesis that the elevated levels of hdm2 expression reported in cancers such as ERalpha(+ve) breast tumors play an important role in the development of these tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750288

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Authors:  Lynn Biderman; Masha V Poyurovsky; Yael Assia; James L Manley; Carol Prives
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

2.  Expression of the Bcl-3 proto-oncogene suppresses p53 activation.

Authors:  David Kashatus; Patricia Cogswell; Albert S Baldwin
Journal:  Genes Dev       Date:  2005-12-29       Impact factor: 11.361

3.  Regulation of expression of the rat orthologue of mouse double minute 2 (MDM2) by H(2)O(2)-induced oxidative stress in neonatal rat cardiac myocytes.

Authors:  Sampsa Pikkarainen; Robert A Kennedy; Andrew K Marshall; El Li Tham; Kenneth Lay; Thomas A Kriz; Balvinder S Handa; Angela Clerk; Peter H Sugden
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

Review 4.  MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.

Authors:  Yan Li; Hongjin Zhao; Li Sun; Linjuan Huang; Qifeng Yang; Beihua Kong
Journal:  Hum Cell       Date:  2011-03-04       Impact factor: 4.174

5.  p53 Dynamically Directs TFIID Assembly on Target Gene Promoters.

Authors:  R A Coleman; Z Qiao; S K Singh; C S Peng; M Cianfrocco; Z Zhang; A Piasecka; H Aldeborgh; G Basishvili; W L Liu
Journal:  Mol Cell Biol       Date:  2017-06-15       Impact factor: 4.272

Review 6.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

Review 8.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

9.  Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.

Authors:  Moussa Alkhalaf; Abdalla M El-Mowafy; Laila A Abou-Zeid
Journal:  J Mol Genet Med       Date:  2005-08-19

10.  Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Authors:  Charles N Birts; Rachael Harding; Gehan Soosaipillai; Trisha Halder; Ali Azim-Araghi; Matthew Darley; Ramsey I Cutress; Adrian C Bateman; Jeremy P Blaydes
Journal:  Biol Cell       Date:  2010-01       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.